Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection

Treatment of chronic viral infections accompanied by permanent virus persistence in the target epitopes of the oral cavity, skin, urogenital tract is complicated by virtual lack of available drugs exerting combined systemic virulicidal and immunomodulatory effects. Here we demonstrate clinical and i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	V. A. Zurochka, O. I. Zabkov, M. A. Dobrynina, V. F. Gritsenko, E. V. Davydova, A. V. Chukichev, N. A. Zabokritskii, A. P. Sarapultsev, A. V. Zurochka
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2020
Materias:	epstein–barr virus infection valacyclovir glucosaminilmuramildipeptide cosmetic “acegram” antiviral activity flow cytometry enzyme-linked immunosorbent assay polymerase chain reaction lymphocytes immune status Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/6f8ae2a011984f6db0e2e33dd0e78757
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f8ae2a011984f6db0e2e33dd0e78757
record_format	dspace
spelling	oai:doaj.org-article:6f8ae2a011984f6db0e2e33dd0e787572021-11-22T07:09:53ZClinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection2220-76192313-739810.15789/2220-7619-CDC-1141https://doaj.org/article/6f8ae2a011984f6db0e2e33dd0e787572020-05-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1141https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Treatment of chronic viral infections accompanied by permanent virus persistence in the target epitopes of the oral cavity, skin, urogenital tract is complicated by virtual lack of available drugs exerting combined systemic virulicidal and immunomodulatory effects. Here we demonstrate clinical and immunological efficacy of combined therapy in treatment of Epstein–Barr virus (EBV)-associated chronic infections. The aim of the study was to evaluate the clinical and immunological efficacy of combined etiopathogenetic therapy using the Acegram cosmetic product in patients with EBV-associated chronic infections. Materials and methods. There were enrolled 40 patients monitored before treatment as well as 20 patients followed up after combination therapy (cycle therapy consisted of oral valaciclovir (Valtrex) applied at dose of 500 μg twice a day for 10 days, glucosaminylmuramyldipeptide (Licopid) — 10 mg 2 twice a day for 10 days, topical irrigation for mucous membranes with granulocyte-macrophage colony-stimulating factor active center-derived peptide (Acegram-spray) 3 times a day for 10 days. If necessary, treatment courses were repeated 20 days after the onset. All patients were examined for the presence of EBV genomes in the oral fluid and blood using the qualitative and quantitative polymerase chain reaction (PCR) using the DNA technology test system (Russia) on a DT-Lite device prior treatment and 30, 60 days post-therapy time points. In addition, serum samples were analyzed for level of class G immunoglobulins specific to the EBV nuclear and capsid antigens by using enzyme immunoassay (test systems manufactured by CJSC Vector Best, Russia) as well as immune status (clinical methods, enu flow cytometry evaluation of the phagocytic activity of neutrophils, ELISA method). Results. Use of single or two course combination therapy in subjects with fully eradicated EBV carriage associated with reversed clinical symptoms was accompanied by recovered immune system status (T and B cells, T-helper cells, CD3+ CD25+ cells, phagocytosis parameters). A non-invasive approach proposed for controlling virus elimination in the oral fluid by using polymerase chain reaction method may serve as to objectively monitor therapeutic efficacy.V. A. ZurochkaO. I. ZabkovM. A. DobryninaV. F. GritsenkoE. V. DavydovaA. V. ChukichevN. A. ZabokritskiiA. P. SarapultsevA. V. ZurochkaSankt-Peterburg : NIIÈM imeni Pasteraarticleepstein–barr virus infectionvalacyclovirglucosaminilmuramildipeptidecosmetic “acegram”antiviral activityflow cytometryenzyme-linked immunosorbent assaypolymerase chain reactionlymphocytesimmune statusInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 10, Iss 2, Pp 338-346 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	epstein–barr virus infection valacyclovir glucosaminilmuramildipeptide cosmetic “acegram” antiviral activity flow cytometry enzyme-linked immunosorbent assay polymerase chain reaction lymphocytes immune status Infectious and parasitic diseases RC109-216
spellingShingle	epstein–barr virus infection valacyclovir glucosaminilmuramildipeptide cosmetic “acegram” antiviral activity flow cytometry enzyme-linked immunosorbent assay polymerase chain reaction lymphocytes immune status Infectious and parasitic diseases RC109-216 V. A. Zurochka O. I. Zabkov M. A. Dobrynina V. F. Gritsenko E. V. Davydova A. V. Chukichev N. A. Zabokritskii A. P. Sarapultsev A. V. Zurochka Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
description	Treatment of chronic viral infections accompanied by permanent virus persistence in the target epitopes of the oral cavity, skin, urogenital tract is complicated by virtual lack of available drugs exerting combined systemic virulicidal and immunomodulatory effects. Here we demonstrate clinical and immunological efficacy of combined therapy in treatment of Epstein–Barr virus (EBV)-associated chronic infections. The aim of the study was to evaluate the clinical and immunological efficacy of combined etiopathogenetic therapy using the Acegram cosmetic product in patients with EBV-associated chronic infections. Materials and methods. There were enrolled 40 patients monitored before treatment as well as 20 patients followed up after combination therapy (cycle therapy consisted of oral valaciclovir (Valtrex) applied at dose of 500 μg twice a day for 10 days, glucosaminylmuramyldipeptide (Licopid) — 10 mg 2 twice a day for 10 days, topical irrigation for mucous membranes with granulocyte-macrophage colony-stimulating factor active center-derived peptide (Acegram-spray) 3 times a day for 10 days. If necessary, treatment courses were repeated 20 days after the onset. All patients were examined for the presence of EBV genomes in the oral fluid and blood using the qualitative and quantitative polymerase chain reaction (PCR) using the DNA technology test system (Russia) on a DT-Lite device prior treatment and 30, 60 days post-therapy time points. In addition, serum samples were analyzed for level of class G immunoglobulins specific to the EBV nuclear and capsid antigens by using enzyme immunoassay (test systems manufactured by CJSC Vector Best, Russia) as well as immune status (clinical methods, enu flow cytometry evaluation of the phagocytic activity of neutrophils, ELISA method). Results. Use of single or two course combination therapy in subjects with fully eradicated EBV carriage associated with reversed clinical symptoms was accompanied by recovered immune system status (T and B cells, T-helper cells, CD3+ CD25+ cells, phagocytosis parameters). A non-invasive approach proposed for controlling virus elimination in the oral fluid by using polymerase chain reaction method may serve as to objectively monitor therapeutic efficacy.
format	article
author	V. A. Zurochka O. I. Zabkov M. A. Dobrynina V. F. Gritsenko E. V. Davydova A. V. Chukichev N. A. Zabokritskii A. P. Sarapultsev A. V. Zurochka
author_facet	V. A. Zurochka O. I. Zabkov M. A. Dobrynina V. F. Gritsenko E. V. Davydova A. V. Chukichev N. A. Zabokritskii A. P. Sarapultsev A. V. Zurochka
author_sort	V. A. Zurochka
title	Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_short	Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_full	Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_fullStr	Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_full_unstemmed	Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_sort	clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic epstein–barr virus infection
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2020
url	https://doaj.org/article/6f8ae2a011984f6db0e2e33dd0e78757
work_keys_str_mv	AT vazurochka clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection AT oizabkov clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection AT madobrynina clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection AT vfgritsenko clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection AT evdavydova clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection AT avchukichev clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection AT nazabokritskii clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection AT apsarapultsev clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection AT avzurochka clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
_version_	1718417922820407296

Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection

Ejemplares similares